Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer

Revathi Kollipara, Bryan Schneider, Milan Radovich, Sunil Babu, Patrick J. Kiel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 62-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab. This led to substantial regression of tumor nodules. Genomic sequencing-based approaches to identify therapeutic targets has potential for improving outcomes. Currently, the patient continues to be in complete radiographic and clinical remission 20 months after beginning treatment with nivolumab

Original languageEnglish (US)
Pages (from-to)1149-1151
Number of pages3
JournalOncologist
Volume22
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Immunotherapy
Drug Therapy
Thyroidectomy
Therapeutics
Lymph Node Excision
Neoplasms
Radiation
Ligands
Anaplastic Thyroid Carcinoma
nivolumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. / Kollipara, Revathi; Schneider, Bryan; Radovich, Milan; Babu, Sunil; Kiel, Patrick J.

In: Oncologist, Vol. 22, No. 10, 01.10.2017, p. 1149-1151.

Research output: Contribution to journalArticle

Kollipara, Revathi ; Schneider, Bryan ; Radovich, Milan ; Babu, Sunil ; Kiel, Patrick J. / Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. In: Oncologist. 2017 ; Vol. 22, No. 10. pp. 1149-1151.
@article{bc1c93c1e67e474fb70b82723c252744,
title = "Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer",
abstract = "Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 62-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab. This led to substantial regression of tumor nodules. Genomic sequencing-based approaches to identify therapeutic targets has potential for improving outcomes. Currently, the patient continues to be in complete radiographic and clinical remission 20 months after beginning treatment with nivolumab",
author = "Revathi Kollipara and Bryan Schneider and Milan Radovich and Sunil Babu and Kiel, {Patrick J.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1634/theoncologist.2017-0096",
language = "English (US)",
volume = "22",
pages = "1149--1151",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer

AU - Kollipara, Revathi

AU - Schneider, Bryan

AU - Radovich, Milan

AU - Babu, Sunil

AU - Kiel, Patrick J.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 62-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab. This led to substantial regression of tumor nodules. Genomic sequencing-based approaches to identify therapeutic targets has potential for improving outcomes. Currently, the patient continues to be in complete radiographic and clinical remission 20 months after beginning treatment with nivolumab

AB - Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 62-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab. This led to substantial regression of tumor nodules. Genomic sequencing-based approaches to identify therapeutic targets has potential for improving outcomes. Currently, the patient continues to be in complete radiographic and clinical remission 20 months after beginning treatment with nivolumab

UR - http://www.scopus.com/inward/record.url?scp=85034095885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034095885&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0096

DO - 10.1634/theoncologist.2017-0096

M3 - Article

VL - 22

SP - 1149

EP - 1151

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -